文献速递真菌感染新发突发、热带与寄生虫病

流感相关ARDS危重患者经验性抗真菌治疗:倾向评分加权观察性研究

Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

多中心观察性研究纳入172例流感相关ARDS的ICU患者,61例(35%)接受经验性抗真菌治疗(94%为泊沙康唑)。经验性治疗组30天IAPA发生率为7.7%,非治疗组为20.4%(P=.002),校正后sHR为0.21(95%CI:0.10-0.92,P=.045),但30天ICU生存无显著差异。

要点

  • 经验性抗真菌治疗与流感相关ARDS患者30天IAPA发生率显著降低相关。
  • 该治疗未转化为30天ICU生存获益。
  • IAPA中位起病为ICU入科后2天,需早期识别高危患者。

核心结论

  • 在流感相关ARDS的ICU患者中,经验性抗真菌治疗与IAPA发生率显著降低相关,但未改善30天ICU生存。

研究设计与样本

  • 多中心观察性研究,共9个治疗中心,纳入2016年9月1日至2025年3月1日连续入ICU的流感相关ARDS患者,共172例,采用倾向评分加权校正基线特征。

主要发现

  • 61例(35%)接受经验性抗真菌治疗,其中94%使用泊沙康唑。
  • 共诊断IAPA 24例,中位起病为ICU入科后2天,非治疗组20例、经验性治疗组4例。
  • 30天IAPA发生率治疗组7.7%、非治疗组20.4%(P=.002)。
  • 经验性治疗组相比非治疗组的IAPA发生sHR为0.21(95%CI:0.10-0.92,P=.045)。
  • 30天ICU生存两组间无显著差异。

关键数值与推荐

  • IAPA病例依据FUNDICU共识标准分类。
  • 经验性抗真菌治疗组30天IAPA发生率7.7%,非治疗组20.4%(P=.002)。
  • IAPA发生sHR 0.21(95%CI:0.10-0.92,P=.045)。

临床怎么用

  • 对流感相关ARDS的ICU患者可考虑经验性抗真菌治疗以降低IAPA发生,但需权衡其未带来生存获益,并等待随机对照试验验证。

局限性

  • 为观察性研究,即使采用倾向评分加权仍可能存在未测量混杂。
  • 经验性治疗组样本量较小(61例),生存分析可能把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear. METHODS: In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria. RESULTS: We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10-0.92, P = .045). However, there was no significant difference in 30-day ICU survival. CONCLUSIONS: In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients' specific empirical antifungal treatment with regard to IAPA incidence and outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hatzl S, Kriegl L, Geiger C, et al. Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study. Clin Infect Dis. 2026. PMID: 40971881. doi:10.1093/cid/ciaf507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。